Last reviewed · How we verify

NCT04204512: ECHORTON

Comparison of 22Mhz and 18Mhz High-frequency Probes for the Ultrasound Study of Temporal Arteries in Patients Suspected of Having Giant Cell Arteritis

Completed Last updated 24 August 2021
What this trial tests

trial in Giant Cell Arteritis in 80 participants. Completed in 24 August 2020.

Timeline
17 December 2019
Primary endpoint
24 August 2020
24 August 2020

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusCompleted
Study typeOBSERVATIONAL
Enrollment80
Start date17 December 2019
Primary completion24 August 2020
Estimated completion24 August 2020
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

50 and older, any sex, with Giant Cell Arteritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the structural features of temporal arteritis using two frequencies probes: 18 and 22Mhz.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Current developments in the diagnosis and treatment of giant cell arteritis.
    Szekeres D, Al Othman B. · · 2022 · cited 5× · PMID 36582285 · DOI 10.3389/fmed.2022.1066503

Verify or expand the search:

Other recruiting trials for Giant Cell Arteritis

Currently open trials in the same condition.

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04204512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing